Around the Practice: Optimizing Patient Care for Advanced Non–Clear Cell RCC

Medical experts give an overview of renal cell carcinoma (RCC), detailing the differences between clear cell and non–clear cell subtypes, the various forms of non–clear cell RCC, and the demographic and risk factor profiles associated with each subtype, while also discussing how histological differences influence prognosis.

Medical experts explore the main challenges in treating non–clear cell RCC compared with clear cell RCC, discussing how these difficulties vary between community and academic settings.

Medical experts outline the current first-line treatment options for advanced non–clear cell RCC, including the factors influencing agent selection, as well as discuss how recent NCCN guideline updates and label changes affect treatment decisions in community practice.

Medical experts review long-term data from the KEYNOTE-B61 trial on pembrolizumab and lenvatinib, compare its efficacy and safety across non–clear cell RCC subtypes, and discuss dose management and safety relative to the CLEAR trial.

Medical experts discuss clinical trials supporting alternative therapies for advanced non–clear cell RCC, including Cabo alone, Nivo + Cabo, and others, and whether these studies covered all histologies.

Medical experts explore how non–clear cell RCC histology impacts treatment selection, addressing challenges with less common subtypes vs more frequent ones, and discuss how clinical data and experience inform treatment sequencing and shared decision-making.

Medical experts discuss significant adverse effects of TKIs and IOs, including management and patient education, and highlight exciting pipeline therapies for non–clear cell RCC, such as Ipi + Nivo and zanzalintinib + Nivo.

Medical experts examine how overall survival data from KEYNOTE-564 has influenced the use of pembrolizumab as adjuvant therapy.

Medical experts will discuss the updated NCCN guidelines favoring ipilimumab + plus nivolumab for patients with favorable risk, including the data supporting this change and its the potential impact on the disease landscape.

Medical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.